Prevention of experimental coronavirus colds with intranasal alpha-2b interferon

Fifty-five volunteers treated with either intranasal recombinant interferon (rIFN; 2 X 10(6) IU/day) or placebo for 15 days were exposed to coronavirus by direct intranasal inoculation on the eighth day of treatment. Symptom scores were recorded, and cultures of virus were taken daily for all volunt...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1986-09, Vol.154 (3), p.443-447
Main Authors: Turner, R B, Felton, A, Kosak, K, Kelsey, D K, Meschievitz, C K
Format: Article
Language:English
Subjects:
Administration, Intranasal
alpha -interferon
Antigens, Viral - analysis
Clinical Trials as Topic
common cold
Common Cold - prevention & control
Coronaviridae Infections - prevention & control
coronavirus (man)
Double-Blind Method
Enzyme-Linked Immunosorbent Assay
Interferon Type I - administration & dosage
Interferon Type I - therapeutic use
man
Random Allocation
Recombinant Proteins - administration & dosage
Recombinant Proteins - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fifty-five volunteers treated with either intranasal recombinant interferon (rIFN; 2 X 10(6) IU/day) or placebo for 15 days were exposed to coronavirus by direct intranasal inoculation on the eighth day of treatment. Symptom scores were recorded, and cultures of virus were taken daily for all volunteers for seven days after inoculation. Nineteen (73%) of the 26 placebo recipients met symptom-score criteria for a cold, compared with 12 (41%) of the IFN recipients (P = .02). The mean nasal symptom scores in the placebo and IFN groups were 9.2 and 5.4, respectively (P = .03), and the mean total symptom scores in the two groups were 23.2 and 9.4, respectively (P = .003). The mean number of days with a total symptom score greater than 4 was 1.6 in the placebo recipients and 0.5 in the rIFN recipients (P = .02). Prophylactic intranasal rIFN effectively shortened the duration and reduced the severity of coronavirus cold symptoms.
ISSN:0022-1899
DOI:10.1093/infdis/154.3.443